+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 130Years
All Genders
ID05774951

Camizestrant Compared to Standard Endocrine Therapy for ERHER2- Early Breast Cancer at Intermediate or High Recurrence Risk After Prior Endocrine Treatment

Led by AstraZeneca · Updated on 2026-10-13

4300

Participants Needed

709

Research Sites

475 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

CONDITIONS

Brief Title

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Team

A

AstraZeneca Clinical Study Information Center

A

AstraZeneca Breast Cancer Study Locator Service

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here